Placebo News and Research

RSS

Neurovance closes $6.3M extension to its series A1 financing round to advance development of EB-1020 SR

Neurovance, Inc. today announced that it has closed a $6.3 million extension to its series A1 financing round to further advance development of EB-1020 SR, a non-stimulant, for the treatment of all subtypes of adult ADHD (attention deficit hyperactivity disorder).

3 Apr 2014

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

BioDelivery Sciences International, Inc. announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy.

3 Apr 2014

CardioCell receives IND approval for Phase IIa clinical study of itMSC therapy to treat heart failure

CardioCell LLC has just received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with chronic heart failure (CHF), which generates more than 1 million hospitalizations annually.

3 Apr 2014

Kessler Foundation receives grant to study effect of speed of processing training on cognitive performance in MS

Kessler Foundation received a four-year $750,000 grant from the National Multiple Sclerosis Society to conduct a randomized controlled trial of speed of processing training to improve cognition in multiple sclerosis (MS).

3 Apr 2014

Vestiage completes R&D for two new products

Vestiage™, Inc., the emerging leader in healthy aging, announced today that it has completed R&D for two new products that it intends to launch in upcoming quarters.

2 Apr 2014

FDA approves ORALAIR sublingual allergy immunotherapy tablet

GREER Laboratories, Inc., a leading developer and provider of allergy immunotherapy products and services, today announced that the U.S. Food and Drug Administration has approved ORALAIR (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) sublingual allergy immunotherapy tablet.

2 Apr 2014

Oxytocin promotes group-serving dishonesty, says study

According to a new study by researchers at Ben-Gurion University of the Negev (BGU) and the University of Amsterdam, oxytocin caused participants to lie more to benefit their groups, and to do so more quickly and without expectation of reciprocal dishonesty from their group.

2 Apr 2014

Study on effect of Botox on depression

In the largest randomized, double-blind, placebo controlled study to date on the effect of OnabotulinumtoxinA (as known as Botox) on depression, researchers found that more than half of subjects suffering from moderate to severe depression showed a substantial improvement (greater than or equal to 50% of baseline) in their depressive symptoms as measured by the MADRS scale.

2 Apr 2014

Study finds that baclofen drug has potential to prevent cocaine relapse

Relapse is the most painful and expensive feature of drug addiction-even after addicted individuals have been drug-free for months or years, the likelihood of sliding back into the habit remains high. The National Institute on Drug Abuse estimates that 40 to 60 percent of addicted individuals will relapse, and in some studies the rates are as high as 80 percent at six months after treatment.

2 Apr 2014

Bayer’s Adempas now available in the UK to treat patients with CTEPH

Adempas (riociguat) is available in the UK today as the first drug treatment for CTEPH, to treat adult patients with WHO Functional Class (FC) II to III with inoperable or persistent disease to improve exercise capacity.

1 Apr 2014

U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Supreme Court has granted the Company's COPAXONE® certiorari petition and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the "'808 patent").

1 Apr 2014

Clonidine increases hypotension and non-fatal cardiac arrest after noncardiac surgery

Clonidine - a drug that reduces blood pressure and heart rate - increased rates of clinically concerning hypotension and non-fatal cardiac arrest after noncardiac surgery, according to the POISE-2 trial presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

Perioperative aspirin increases risk of serious bleeding after non-heart-related surgery

Patients given aspirin to prevent heart problems after non-heart-related surgery had a higher risk of serious bleeding than the patients who did not receive aspirin.

1 Apr 2014

Study shows administering steroids during cardiac surgery requiring bypass can cause harm

Giving patients steroids at the time of heart surgery does not improve health outcomes and appears to put them at greater risk of having a heart attack in the days following surgery, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

Injecting bone marrow derived stem cells directly into heart muscle improves heart function

Patients with severe ischemic heart disease and heart failure can benefit from a new treatment in which stem cells found in bone marrow are injected directly into the heart muscle, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

Geographical variation in antipsychotic efficacy not ruled out

An individual patient data meta-analysis fails to exclude the possibility that atypical antipsychotics work better in patients from some parts of the world than others.

31 Mar 2014

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

rEVO Biologics Inc., a subsidiary of LFB SA, today announced the initiation of the Phase 3 clinical program for ATryn for the treatment of preeclampsia in pregnant women during the 24th to 28th week of pregnancy.

31 Mar 2014

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.

31 Mar 2014

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Prana Biotechnology has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease ("IMAGINE" Trial), based on draft results.

31 Mar 2014

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

31 Mar 2014

Placebo News and Research

Neurovance closes $6.3M extension to its series A1 financing round to advance development of EB-1020 SR

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

CardioCell receives IND approval for Phase IIa clinical study of itMSC therapy to treat heart failure

Kessler Foundation receives grant to study effect of speed of processing training on cognitive performance in MS

Vestiage completes R&D for two new products

FDA approves ORALAIR sublingual allergy immunotherapy tablet

Oxytocin promotes group-serving dishonesty, says study

Study on effect of Botox on depression

Study finds that baclofen drug has potential to prevent cocaine relapse

Bayer’s Adempas now available in the UK to treat patients with CTEPH

U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

Clonidine increases hypotension and non-fatal cardiac arrest after noncardiac surgery

Perioperative aspirin increases risk of serious bleeding after non-heart-related surgery

Study shows administering steroids during cardiac surgery requiring bypass can cause harm

Injecting bone marrow derived stem cells directly into heart muscle improves heart function

Geographical variation in antipsychotic efficacy not ruled out

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News